Wuxi Zhikang Hongren New Drug Development

Wuxi Zhikang Hongren New Drug Development is a clinical-stage biotechnology company headquartered in Wuxi, China, dedicated to the discovery and development of innovative therapies for metabolic diseases. The company primarily focuses on the incretin pathway, developing a pipeline of long-acting peptides that target the GLP-1, GIP, and glucagon receptors. Their lead candidate, ZK002, is a GLP-1 receptor agonist currently in Phase 2 clinical trials for the treatment of type 2 diabetes. Additionally, the company is advancing multi-target agonists like ZK003 and ZK005 to address obesity and metabolic-associated steatohepatitis (MASH). Zhikang Hongren leverages its expertise in peptide engineering to create differentiated treatments with improved efficacy and dosing convenience for patients worldwide.